TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9.
7.263 Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:
perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2008;15(suppl. 1):98-102.
7.264 Cornely OA et al. Current experience in treating invasive zygomycosis with posaconazole. Clin
Micro-biol Infect 2009;15(suppl. 1):77-81.
7.265 van Burik JA et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary
of 93 cases. Clin Infect Dis 2006;42:e61-5.
7.266 Keating GM. Posaconazole. Drugs 2005;65:1553-67.
7.267 Greenberg RN et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother
2006;50:126-33.
7.268 Reed C et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.
Clin Infect Dis 2008;47:364-71.
7.269 Tragiannidis A et al. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis.
Clin Microbiol Infect 2009;15(suppl. 1):82-6.
7.270 Mastroianni A. Paranasal sinus mucormycosis in an immunocompetent host: efficacy and safety of
combination therapy with liposomal amphotericin B and adjuvant rHuGM-CSF. Infez Med 2004;4:
278-83.
7.271 Spellberg B et al. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010,12:
423-9.
7.272 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31.
7.273 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma,
phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63.
7.274 Ahmed AO et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet
Infect Dis 2004;4:566-74.
7.275 Ramos-e-Silva M et al. Paracoccidioidomycosis. Dermatol Clin 2008;26:257-69.
7.276 Travassos LR et al. Treatment options for paracoccidioidomycosis and new strategies investigated.
Expert Rev Anti Infect Ther 2008;6:251-62.
7.277 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31.
7.278 Vanittanakom N et al. Penicillium marneffei infection and recent advances in the epidemiology and
molecular biology aspects. Clin Microbiol Rev 2006;19:95-110.
7.279 Sirisanthana T et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei
infection in human immunodeficiency virus infected patients. Clin Infect Dis 1998;26:1107-10.
7.280 Sirisanthana T et al. Epidemiology and management of penicilliosis in human immunodeficiency virus
infected patients. Int J Infect Dis 1998;3:48-53.
7.281 Ustianowski AP et al. Penicillium marneffei infection in HIV. Curr Opin Infect Dis 2008;21:31-6.
7.282 Pastor FJ et al. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol
Infect 2008;14:734-46.
7.283 Steinbach WJ et al. Scedosporium species infections and treatments. J Chemother 2003;15(suppl.
2):16-27.
7.284 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31.
7.285 Revankar SG et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect
Dis 2002;34:467-76.
7.286 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43
(suppl. 1):S3-14.
7.287 Ben-Ami R et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009;48:1033-
41.
7.288 Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am 2006;20:609-20.
7.289 Li DM et al. Cerebral phaeohyphomycosis – a cure at what lengths? Lancet Infect Dis 2009;9:376-
83.
7.290 Bhat SV et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease:
successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007;39:
87-90.
7.291 Revankar SG et al. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin
Infect Dis 2004;38:206-16.
7.292 Perfect JR et al. Voriconazole treatment for less common, emerging or refractory fungal infections.
Clin Infect Dis 2003;36:1122-31.
7.293 Troke P et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
Antimicrob Agents Chemother 2008;52:1743-50.
7.294 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma,
phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63.
7.295 Stringer JR et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect
Dis 2002;8:891-6.
7.296 Calderón EJ et al. Pneumocystis infections in humans: diagnosis and treatment. Expert Rev Anti Infect
Ther 2010;8:683-701.
7.297 Tasaka S et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007;131:
1173-80.
7.298 Walzer PD et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected
patients: 1985-2006. Clin Infect Dis 2008;46:625-33.
7.299 Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia
over the course of the AIDS epidemic. Clin Infect Dis 2008;46:634-6.
7.300 Thomas CF et al. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.
7.301 Kovacs JA et al. New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii
pneumonia. J Am Med Assoc 2001;286:2450-60.
7.302 Kovacs JA et al. Evolving health effects of Pneumocystis. One hundred years of progress in diagnosis
and treatment. J Am Med Assoc 2009;301:2578-85.
7.303 Benfield T et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia.
A case series and systematic review. J Acquir Immune Defic Syndr 2008;48:63-7.
7.304 Cortez KJ et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008;21:157-97.
7.305 Lamaris GA et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases 1989-